- Home
- Media Center
- Press releases
- Medical technologies
Medical technologies
U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options
Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology
The TECNIS PC-IOL Portfolio Powered by InteliLight delivers the best* contrast and low-light performance across the PC-IOL category1,2,3 TECNIS Symfony OptiBlue is now available in the U.S. and select countries in EMEA
Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology
The OCTARAY™ Mapping Catheter with TRUEref™ Technology provides physicians with the precise information needed for catheter ablation procedures that treat cardiac arrhythmias[1],[2],[‡]
New ERLEADA® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Real-world evidence study demonstrates majority of patients with mCSPC achieved over 90 percent decline in PSA by six months after initiation of ERLEADA® Rapid and deep PSA decline is associated with improved health-related quality of life in advanced prostate cancer as shown by separate post-hoc analysis of patient-reported outcomes from Phase 3 SPARTAN and TITAN studies
U.S. FDA Approves New MENTOR® MemoryGel BOOST™ Breast Implant
Implant provides the natural feel patients desire with increased form stability to shape the breast Recent study shows patients and surgeons both preferred the MENTOR® MemoryGel BOOST™ Breast Implant as feeling more like a natural breast versus another leading brand
Johnson & Johnson Medical Devices Companies Announces Strategic Partnership with Microsoft to Further Enable its Digital Surgery Solutions
Collaboration will support a secure, compliant and unified platform to improve customer experience and patient outcomes Combined expertise from both companies poised to make a significant impact in MedTech
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Data presented at ASH 2021 show 83 percent of patients achieved a stringent complete response at median follow-up of 22-months 92 percent of evaluable patients achieved minimal residual disease negativity, with progression-free survival and overall survival sustained in those patients for ≥6 and ≥12 months
DePuy Synthes’ VELYS Robotic-Assisted Solution Paves the Way For Next Generation Knee Replacement Surgery In Australia With The First Clinical Case At Mater Hospital In Sydney
Patients at Sydney’s Mater Hospital are the first in Australia to experience the next generation in robotic assisted surgery. Mater’s surgical team trained on the VELYSTM Robotic-Assisted Solution using the Johnson & Johnson Institute’s first-of-its-kind in Australia Mobile Training Lab and Virtual Reality technology. VELYS Robotic-Assisted Solution helps address challenges cited with robotic assisted technologies on operational efficiencies by helping to simplify surgeons’ existing workflow.[i][ii]